Charles-Schoeman et al. ORAL Surveillance. PE risk factors - History VTE, antidepressant use, obesity, steroids, male, age, OCP/HRT. PPI protective @RheumNow #EULAR2022 POS0239 https://t.co/fDLKrpvpgI

Can we predict VTEs from JAKi for RA at all? Baseline elevated D-dimer pts who go on to develop VTE (but not baseline CRP, so not just general inflamm) Questions raised about effect modification for VTE following JAKi too. This story not yet done OP0269 #EULAR2022 @RheumNow https://t.co/ErDcFpXXUl

Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly they look the same. Great to see given negative clinical impact of recent supply problems with originator. @RheumNow #EULAR2022 POS0287 https://t.co/EqwINwcm7M

Long-term low-dose steroids for RA: can it be weaned? Weaning after 2y of blinded add-on in RA: either PNL 5mg/d or placebo No substantial evidence of adrenal insufficiency - symptoms same - cortisol/ACTH same It's never too late to wean the pred! OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb

#EULAR2022 OP0274 Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease: ⭐️9% with RA, 6% with PsA and AS in Western Australia ⭐️Decrease overall since 1985, but recent increase ⭐️Sharp rise of mycotic infections ⭐️No PJP, likely due to ppx @Rheumnow

Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE

RA & dementia - it's getting more damning RA dementia risk: HR 1.25 from Korean nationwide data: RA n=138,592 this follows @MyasoedovaElena's data RA systemic inflamm leading to dementia (AD, vascular)? Need to understand if any DMARD protective OP0271 #EULAR2022 @RheumNow https://t.co/4V7fOtVlnj

#EULAR2022 OP0275: RA-ILD after transplant by @AARazmjou ⭐️UIP #1 cause RA-ILD, worst prognosis - 68% of transplanted pts ⭐️UIP seen in 88% of deceased patients, 56% of living ⭐️Median survival 5.3 years @RheumNow https://t.co/tGBQ5GBlVg

#EULAR2022 OP0273 Difficult to treat RA (D2TRA): ⭐️Lower socioeconomic treatment ⭐️RF positivity ⭐️Higher inflammatory markers ⭐️ILD ⭐️Lower proportion on MTX, better response to JAKi and RTX @RheumNow

GLORIA trial presented by Martin Boxers. 2 yr RCT, 5mg Pred vs. PBO shows DAS28 benefit (-0.37 to -0.62) & -1.7 better X-ray (vs PBO) at 2yrs. BUT signif more harm (AE) RR 1.24; mostly infx. Is this a good trade off? Abst# OP0263 #EULAR2022 https://t.co/kBiRYxXXZe